Please provide your email address to receive an email when new articles are posted on . Postmenopausal women experienced more widespread vertebral bone accrual at the lumbar spine at 12 months of ...
AUSTIN, Texas – One year of romosozumab (Evenity) followed by 1 year of denosumab (Prolia, Xgeva) was associated with improved bone mineral density (BMD) and lower fracture incidence compared with 2 ...
October 16, 2012 (Minneapolis, Minnesota) — The human sclerostin antibody CDP7851/AMG 785, newly named romosozumab, shows efficacy in rapidly increasing bone mineral density (BMD) at the lumbar spine ...
The investigational humanized monoclonal antibody romosozumab (Amgen and UCB Pharma) increases bone mineral density (BMD) and bone formation and reduces bone resorption in postmenopausal women with ...
Please provide your email address to receive an email when new articles are posted on . The Endocrine Society updated its osteoporosis clinical practice guideline to include recommendations for ...
Romosozumab significantly increases bone mineral density and bone content compared with teriparatide
A new study shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also ...
Amgen, a biotechnology company, and UCB, a global biopharmaceutical company, announced top-line results from the phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis ...
AmgenAMGN and UCB UCBJF announced top-line results from the phase III multi-center, international, randomized, double-blind, placebo-controlled, parallel-group FRActure study in postmenopausal woMen ...
Peter L. Salgo, MD: Based on all this, I know you said there were data. There were trials. I’ve gotten this written down. I’m not making this up. There’s the FRAME study, and there’s the ARCH study.
(HealthDay)—In an Endocrine Society guideline update, published online in the March issue of the Journal of Clinical Endocrinology & Metabolism, recommendations are presented for the use of ...
THOUSAND OAKS, Calif. and BRUSSELS, Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from several exploratory analyses of the Phase 2 study ...
Targeting a naturally occurring inhibitor of bone formation could signal a new direction for osteoporosis care. Findings from an international phase II clinical trial reported in the New England ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results